Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. European Medical Solutions's annualized net income for the quarter that ended in Dec. 2025 was €1.70 Mil. European Medical Solutions's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €0.85 Mil. Therefore, European Medical Solutions's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 199.77%.
The historical rank and industry rank for European Medical Solutions's Return-on-Tangible-Equity or its related term are showing as below:
STU:AS00'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1366.74 Med: -148.96 Max: 222.31
Current: 222.31
During the past 13 years, European Medical Solutions's highest Return-on-Tangible-Equity was 222.31%. The lowest was -1,366.74%. And the median was -148.96%.
STU:AS00's Return-on-Tangible-Equity is ranked better than 97.99% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs STU:AS00: 222.31
European Medical Solutions (STU:AS00) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
European Medical Solutions Return-on-Tangible-Equity Related Terms
European Medical Solutions Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
European Medical Solutions Return-on-Tangible-Equity Chart
STU:AS00 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, European Medical Solutions's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
European Medical Solutions Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, European Medical Solutions's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where European Medical Solutions's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 199.77% mean?
European Medical Solutions (STU:AS00) has a Return-on-Tangible-Equity of 199.77% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on European Medical Solutions and its competitors. According to the industry distribution chart, European Medical Solutions ranks #24 out of 1195 companies in the Biotechnology industry, placing it in the top 2%.
Is European Medical Solutions' Return-on-Tangible-Equity too high?
European Medical Solutions' current Return-on-Tangible-Equity is 199.77%. Based on the distribution chart, European Medical Solutions ranks #24 out of 1195 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, European Medical Solutions has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, European Medical Solutions ranks #24 out of 1195 companies for Return-on-Tangible-Equity. This places European Medical Solutions in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on European Medical Solutions and its competitors. European Medical Solutions's current Return-on-Tangible-Equity is 199.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
European Medical Solutions (STU:AS00) has a current Return-on-Tangible-Equity of 199.77%. The stock's GF Value™ is €8.16, compared to a current price of €4.72 — trading 42.2% below its estimated fair value. The current Return-on-Tangible-Equity is 199.77%. European Medical Solutions' overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current Return-on-Tangible-Equity is 199.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is European Medical Solutions (STU:AS00) Overvalued in 2026?
Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued.
The current stock price of €4.72 is trading 42.2% below its estimated GF Value™ of €8.16.
Key valuation signals for STU:AS00:
Return-on-Tangible-Equity: 199.77%
GF Value™: €8.16 vs. price of €4.72 (42.2% below fair value)
No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
48GF Score
Get the complete analysis for STU:AS00
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AS00 has been successfully added to your 
